Investors

News Release

<< Back
Strem and Codexis Sign Enzyme Distribution Agreement

NEWBURYPORT, Mass. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Feb. 19, 2013-- Strem Chemicals, Inc., a manufacturer of specialty chemicals for research and development and Codexis, Inc. (NASDAQ: CDXS), a developer of world-leading enzymes and processes for the production of pharmaceuticals, biofuels and bio-based chemicals, today announced the signing of an enzyme distribution agreement.

The agreement grants Strem exclusive distribution rights for the new 100mg CODEX® Screening Kits for Codexis’ popular Transaminase and Ketoreductase enzyme platforms. These enzymes enable efficient conversion of ketones to chiral alcohols or amines.

The screening kits contain enzymes evolved with proprietary CodeEvolver® directed evolution technology. The resulting enzymes are designed to work at industrial process conditions while reducing cost and waste. They will be available through Strem’s overnight delivery service so that researchers are able to quickly screen a small number of diverse biocatalysts to pick the best solution.

“We are pleased to announce this partnership with Strem, a company very well established in the distribution of catalysts to a wide customer base,” said Dr. Peter Seufer-Wasserthal, Senior Vice President, Pharmaceuticals at Codexis. “Based on Strem’s proven network, we are looking forward to giving more customers the opportunity to use industrial enzymes at R&D scale.”

“Strem is pleased to be working with a proven market leader in the field of Biocatalysis,” said Ephraim Honig, Chief Operating Officer at Strem. “The addition of these screening kits broadens the range of synthesis tools we offer our customers and acknowledges the increasingly important role this technology plays in drug discovery and development.”

About Strem Chemicals

Strem Chemicals, Inc., established in 1964, is a privately held manufacturer and marketer of specialty chemicals of high purity. Strem’s key products include catalysts, ligands, organometallics, metal carbonyls and nanomaterials. Its products are used for research and development and commercial scale applications, especially in the pharmaceutical, microelectronics, chemicals and petrochemicals industries. Strem Chemicals also provides custom synthesis, process development and cGMP manufacturing services. For more information visit www.strem.com.

About Codexis, Inc.

Codexis, Inc. is a developer of world-leading enzymes and processes for the production of pharmaceuticals, biofuels and bio-based chemicals. Codexis' product lines include CodeXyme™ cellulase enzymes and CodeXol™ detergent alcohol. Partners and customers include global leaders such as Merck, Pfizer and Arch Pharmalabs. For more information, see www.codexis.com.

Source: Codexis, Inc.

Strem Chemicals, Inc.
Media: press@strem.com
or
Codexis, Inc.
Investors:
Paul Cox, 212-362-1200
ir@codexis.com
Media:
media@codexis.com

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS |

Share Page

X
| E-mail Alerts E-mail Alerts | IR Contacts Contacts | Financial Tear Sheet Tear Sheet

WE ARE BIOCATALYSISTM

We are an industrial biotechnology company delivering real business results through biobased innovation in chemicals, fuels, pharmaceuticals, consumer, and industrial products.

PHARMACEUTICAL ENZYMES


Supporting faster, cleaner, more efficient pharmaceutical manufacturing processes

Codexis delivers a range of chemicals at kilogram to multi-ton scale, through a partnered manufacturing network

CODEXIS

WHAT WE DO


Codexis delivers revolutionary biocatalytic routes that no one else can


CODEXIS

MEDIA CENTER


Visit our Media Center for the latest product information, videos, imagery, technical papers and press information.


CAREERS AT CODEXIS

An opportunity to make a difference.

Continued success at Codexis depends on the innovation, collaboration and commitment of people who are passionate about what they do


CODEXIS

INVESTOR CENTER


Access to Codexis information
for the investment community

built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue